(Q45965286)

English

Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

1 reference

based on heuristic

inferred from title

author name string

Jung Hyun Kwon

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Jeong Won Jang

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Jong Young Choi

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Chung-Hwa Park

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Sun Hong Yoo

5

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Si Hyun Bae

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Seung Kew Yoon

7

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2013

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Journal of Medical Virology

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

85

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

34-42

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Clinical and virological effects of long-term (over 5 years) lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Pretreatment alanine transaminase level may not be the most important predictor of HBeAg loss in the older patient.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23421

21 January 2018

Identifiers

10.1002/JMV.23421

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/23154874

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45965286&oldid=1623208698"